Company Profile
Tokyo, Japan
Heartseed develops and commercializes iPS cell-derived cardiomyocyte replacement therapy for heart failure. The company's lead product is HS-001 for heart failure with reduced ejection fraction indications Including dilated cardiomyopathy, old myocardial infraction, and dilated phase of hypertrophic cardiomyopathy.
It also develops products using autologous iPSC and HLA knock-out iPSC, as well as differentiation induction, mass culture, purification, and myocardial globule production technology. Incorporated in 2015, the company is headquartered in Tokyo, Japan.